EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant

Jingyi Qian iD, Darko Stefanovski, Phillip A K Andersen, Nina Vujovic, Lauren Kelly, Joshua Lepson, Hoa Nguyen, Sean Byrne, Wei Wang, Thomas Mandrup-Poulsen, Gail Adler, Marta Garaulet und 2 weitere

Diabetes Care · 01.08.2026 · 49 (8) · 1498-1506

DOI: 10.2337/dc26-0164 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 25.06.2026. Verfasst von Jingyi Qian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Receptor, Melatonin, MT2, Melatonin, Insulin. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin’s adverse metabolic effects and highlighting the need for a genotype-based personalized approach. We aimed to comprehensively characterize the actions of melatonin on glucose homeostasis, including first- and second-phase β-cell responsivity to glucose, β-cell negative feedback by exogeneous insulin, insulin sensitivity, and whether such effects are stronger in MTNR1B G-allele risk carriers compared with noncarriers. RESEARCH DESIGN AND METHODS Twenty-one healthy participants of European ancestry were studied in a randomized, double-blind, placebo-controlled, crossover trial, including 10 MTNR1B risk carriers and 11 noncarriers. Each participant underwent a highly controlled 5-day laboratory protocol, during which they received 5 mg oral melatonin or placebo in randomized order on two nonconsecutive days. Glycemic dynamics were assessed using insulin-modified intravenous glucose tolerance tests with minimal-model analysis. RESULTS Melatonin worsened glucose tolerance and reduced early C-peptide responses in risk allele carriers (vs. placebo: 11.7% [95% CI 1.0–22.3] and −19.2% [−33.9 to −1.2], respectively; Padj < 0.05) but not in noncarriers. In carriers, impairments stemmed from a 40% (−52.4 to −24.3; Padj = 0.0003) suppression of glucose-stimulated first-phase β-cell responsivity, along with a slower insulin-induced decline in second-phase insulin secretion rate (64.3% [23.1–119.2]; Padj = 0.001). In carriers, melatonin also prevented exogenous insulin-induced hypoglycemia compared with placebo (zero vs. seven events, P = 0.001), but not in noncarriers. CONCLUSIONS These findings identify blunted β-cell responsivity to glucose and dysregulated insulin negative feedback as key mechanisms linking melatonin signaling to diabetes risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Melatonin, MT2MelatoninInsulinHumansMaleInsulin SecretionAdultFemaleCross-Over StudiesDouble-Blind MethodGlucose Tolerance TestDiabetes Mellitus, Type 2Blood GlucoseMiddle AgedInsulin-Secreting Cells

Substanzen

Receptor, Melatonin, MT2MelatoninInsulinMTNR1B protein, humanBlood Glucose

Autor:innen und Institutionen

  • Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA.
  • Division of Sleep Medicine, Harvard Medical School, Boston, MA.
  • Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Mass General Brigham and Harvard Medical School, Boston, MA.
  • Department of Physiology, University of Murcia, Murcia, Spain.

ORCID-Profile: Jingyi Qian, Frank A J L Scheer

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NCRR NIH HHS
  • Harvard University
  • ADA
  • CTSA
  • Independent Research Fund Denmark
  • Brigham and Women's Hospital

Zitieren

APA

Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., Adler, G., Garaulet, M., Saxena, R., & Scheer, F. A. J. L. (2026). Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care, 49(8), 1498-1506. https://doi.org/10.2337/dc26-0164

Vancouver

Qian J, Stefanovski D, Andersen PAK, Vujovic N, Kelly L, Lepson J, et al. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care. 2026;49(8):1498-1506. doi:10.2337/dc26-0164

BibTeX
@article{Qian2026,
  author = {Qian, Jingyi and Stefanovski, Darko and Andersen, Phillip A K and Vujovic, Nina and Kelly, Lauren and Lepson, Joshua and Nguyen, Hoa and Byrne, Sean and Wang, Wei and Mandrup-Poulsen, Thomas and Adler, Gail and Garaulet, Marta and Saxena, Richa and Scheer, Frank A J L},
  title = {Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {8},
  pages = {1498--1506},
  doi = {10.2337/dc26-0164}
}
Kostenlos starten →